Ontogeny

Ontogeny was a pioneering biotechnology company focused on the application of developmental biology to the treatment of human diseases. The company specialized in identifying and developing proteins and small molecules that regulate the growth and differentiation of cells, particularly through the Hedgehog signaling pathway. In 2000, Ontogeny merged with Creative BioMolecules and Reprogenesis to form Curis, Inc. Their research laid the groundwork for significant oncology treatments, including the first-in-class Hedgehog pathway inhibitor vismodegib. The company's platform was built on the work of leading scientists in the field of developmental genetics and regenerative medicine.